A daily tablet combined with chemotherapy has stopped pancreatic cancer tumors from growing in 90% of patients and made them undetectable in roughly 8%, according to clinical trial data presented in Barcelona, an important advance against one of the deadliest and most treatment-resistant malignancies.
Medical experts meeting at the European cancer symposium organized by the EORTC alongside the NCI and AACR discussed findings on the drug daraxonrasib, marketed as Rasonque and developed by Revolution Medicines, BBC News Brasil reported, according to VEJA. The trial tracked 61 participants diagnosed with advanced pancreatic cancer that had metastasized to other parts of the body.
Drug Disables Altered RAS Proteins Driving Pancreatic Tumors
- Targeted Inhibition: The drug works by binding to and disabling altered RAS proteins that drive rapid tumor proliferation in roughly 90% of pancreatic ductal adenocarcinoma cases.
- Interim Realities: While tumor shrinkage and disease stabilization exceeded historical chemotherapy benchmarks, physicians emphasize the regimen is not yet classified as a cure.
Combination Therapy Nearly Doubles Disease Control Duration
The therapeutic strategy targets the KRAS gene mutations that underpin the aggressive nature of pancreatic tumors. Wungki Park, an oncologist at the Memorial Sloan Kettering Cancer Center, said that the combination therapy nearly doubles the duration of disease control compared to historical chemotherapy baselines, according to 24 Horas.

The trial also demonstrated that tumor growth halted in 90.2% of the 61 participants, while lesions became completely undetectable via computed tomography scans in approximately 8.2% of cases.
| Treatment Arm | Progression-Free Survival | Overall Survival | Tumor Control Rate |
|---|---|---|---|
| Daraxonrasib + Chemotherapy | 7.3 to 12.8 months | 12.4 to 13.2 months | 90.2% stabilized |
| Standard Chemotherapy Alone | 3.5 months | 6.7 months | Variable / Shorter duration |
Regulatory Approvals Across Global Health Agencies
The United States Food and Drug Administration granted authorization to daraxonrasib, and subsequently awarded the chemotherapy combination breakthrough therapy designation, Terra reported.
Sam Godfrey of Cancer Research UK said that the results represent the most substantial therapeutic progress for the disease in decades. “What this new medicamento has done is found a way to medicate what before was considered untreatable,” Godfrey told BBC News Brasil.
Despite these regulatory milestones, access remains contingent on national pricing agreements and localized health authority validations across Europe. Elena Garralda, chair of the EORTC–NCI–AACR Symposium 2026, told BBC News Brasil that “these results are encouraging because they show that combination treatment can potentially significantly improve overall patient survival as well as the time until tumors begin to grow again.”

Therapy Limited to Specific RAS Mutations After Prior Treatment
Because pancreatic cancer is frequently diagnosed in advanced stages—as seen in the 2016 death of actor Alan Rickman five months after his diagnosis—early identification remains critical.
Memorial Sloan Kettering Cancer Center traces its origins to the 1884 founding of New York Cancer Hospital by a group including John Jacob Astor III. In 1902, Arabella Huntington established the nation’s first cancer research fund there with a US$100,000 bequest.
The modern institution formed in 1980 from the merger of Memorial Hospital and the Sloan-Kettering Institute for Cancer Research, created in 1945 with a $4 million gift from General Motors chairman Alfred P. Sloan and support from Charles F. Kettering. It is one of 72 National Cancer Institute–designated Comprehensive Cancer Centers.
The targeted therapy is strictly indicated for adults with specific RAS mutations and metastatic disease following prior systemic therapy, and should not be pursued independently without formal oncology oversight. Ongoing phase 3 trials, such as RASolute 303, continue to evaluate the molecule in newly diagnosed populations to determine long-term safety profiles, potential adverse events, and definitive remission rates.
References
- Memorial Sloan Kettering Cancer Center – Pancreatic Cancer Research Updates
- European Organisation for Research and Treatment of Cancer (EORTC) Symposium Proceedings
- Cancer Research UK – Annual epidemiological surveillance data on pancreatic malignancies